OTCM
SYGGF
Market cap20kUSD
Dec 15, Last price
0.00USD
Name
Synairgen PLC
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
362.40%
Rev. 5Y
49.38%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-8m
L-52.35%
CFO
-8m
L-41.89%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Synairgen plc is a biopharmaceutical company focused on the discovery and advancement of therapeutic drugs for various respiratory conditions. Their product pipeline features SNG001, an inhaled interferon beta under development for the treatment of COVID-19. They are also conducting Phase II clinical trials for an inhaled formulation of interferon beta (IFN-ß), targeting both asthma exacerbated by the common cold and flu, and the treatment or prevention of chronic obstructive pulmonary disease (COPD). Furthermore, Synairgen is developing a LOXL2 inhibitor specifically for idiopathic pulmonary fibrosis (IPF) disease. This LOXL2 inhibitor is being developed through a licensing and collaborative agreement with Pharmaxis Ltd. The company was founded in 2004 and is based in Southampton, United Kingdom.
Key people
Non-Executive Chairman of the Board · since 2003
Richard James Marsden
Chief Executive Officer, Executive Director · since 2004
Phillip Monk
Chief Scientific Officer, Executive Director · since 2009
John Ward
Finance Director, Executive Director, Secretary
Iain Peter Murray Buchanan
Non-Executive Director · since 2010
Bruce L Campbell
Non-Executive Director · since 2006
Stephen Holgate
Non-Executive Director · since 2003
Headquarters & legal address
MAILPOINT 810 LEVEL F
SOUTH BLOCK SOUTHAMPTON
GENERAL HOSPITAL TREMONA ROAD
SOUTHAMPTON, STH SO16 6YD
GB
SOUTH BLOCK SOUTHAMPTON
GENERAL HOSPITAL TREMONA ROAD
SOUTHAMPTON, STH SO16 6YD
GB
Previous name
SYNAIRGEN PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||